Allogene Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Allogene Therapeutics Inc 's ROA in the second quarter of 2026?
Allogene Therapeutics Inc recorded a cumulative net loss of $-165 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -25.07%.

However, within the Healthcare sector 468 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3795, from total ROA ranking in the first quarter of 2026 at 4479.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	193.35 %	-22.05 %	-17.66 %	-17.83 %	-18.63 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-165	-174	-191	-212	-237
Return On Assets (TTM)	-25.07 %	-40.17 %	-41.45 %	-43.87 %	-46.71 %
ALLO's Total Ranking	# 3795	# 4479	# 3946	# 4016	# 4072
Total Assets (TTM) in million	1,380	396	424	440	471
Seq. Total Assets Change	248.65 %	-6.6 %	-3.6 %	-6.55 %	-7.36 %
Seq. Net Income Change	-	-	-	-	-

ALLO's 5 Years Annual ROA >> Back to ALLO Management Effectiveness >> Compare ALLO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 55
Sector	# 469
Overall	# 3718

Return On Assets Statistics
High	Average	Low
-10.82 %	-33.55 %	-46.55 %
(Jun 30 2019)		(Sep 30 2024)

Financial Statements
Allogene Therapeutics Inc 's Assets	$ 1,380 million	ALLO's Balance sheet
Allogene Therapeutics Inc 's Income	$ -43 million	Quarterly ALLO's Income Statement
ALLO's Income by Division		See ALLO's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-14.2 %	-13.35 %	-21.88 %	-24.85 %	-17.59 %
Total Assets in million	424	494	570	730	971
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-191	-258	-327	-340	-257
Annual Return On Assets	-45.03 %	-52.13 %	-57.39 %	-46.63 %	-26.46 %

ALLO's 5 Years Annual ROA >> Back to ALLO Management Effectiveness >> Compare ALLO ROA to its Competitors

More Return On Assets Ratios
ALLO's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ALLO's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ALLO's Competitors
Subscribers only: Roa for Allogene Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for ALLO's Customers

You may also want to know
ALLO's Roi	ALLO's Inventory Turnover Ratio	ALLO's Growth Rates	ALLO's Dividend Comparisons
	ALLO's Profitability Ratios	ALLO's Asset Turnover Ratio	ALLO's Dividend Growth
ALLO's Roe	ALLO's Valuation Ratios	ALLO's Financial Strength Ratios	ALLO's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:35:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.